Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date Sort descending | Purpose |
|---|---|---|---|---|---|
| Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) | PAR-23-168 | NIMH | The objective of this funding opportunity announcement (FOA) is to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment… More | ||
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) | PAR-23-157 | NIDA | This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on… More | ||
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required) | PAR-23-158 | NIDA | This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on… More | ||
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) | PAR-23-164 | NIMH | This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single… More | ||
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) | PAR-23-165 | NIMH | This Funding Opportunity Announcement (FOA) invites research grant applications that propose the preclinical development of novel radioligands for positron emission tomography (PET) or single photon… More | ||
| Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) | PAS-23-086 | NIDDK | This Funding Opportunity Announcement encourages the submission ofpilot and feasibilityclinical trialsconducted in humans that will lay the foundation for larger clinical trials related to the… More | ||
| NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) | PAR-23-111 | NIMHD | NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities… More | ||
| NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed) | PAR-23-162 | NIDCR | This Notice of Funding Opportunity (NOFO) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require… More | ||
| Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) | PAR-23-152 | NCI | Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) | ||
| Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) | PAR-23-153 | NCI | Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional) |